



**Telix Pharmaceuticals Limited**  
ACN 616 620 369  
55 Flemington Road  
North Melbourne  
Victoria, 3051  
Australia

## ASX ANNOUNCEMENT

### **Telix Elects to Withdraw from Proposed U.S. Listing**

Melbourne (Australia) – 14 June 2024. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has elected to withdraw its proposed initial public offering (IPO) in the United States.<sup>1</sup>

Given the proposed Nasdaq listing was not predicated on the need to raise capital, Telix's management and Board of Directors have decided not to move forward with the transaction at the terms provided under current market conditions. The Company did not feel that the proposed discounts were aligned with its duty to its existing shareholders.

Since announcing our intention to file (ITF) on the 4 January 2024 (AEDT)<sup>2</sup>, Telix has achieved a number of commercially significant milestones, including positive therapeutic pipeline data readouts, several successful strategic acquisitions and the completion of two further product approval submissions to the U.S. Food and Drug Administration (FDA). This strong performance, augmented by excellent commercial execution in Q1 2024, has resulted in the share price increasing from AUD \$9.53 at ITF to AUD \$16.46 at last trading close, with recent all-time-highs at AUD \$19.06. This represents a significant share price appreciation over the period.

The performance and prospects of the Company remain strong. As a profitable, cash generative company, Telix retains sufficient earnings and balance sheet capacity to deliver on its key corporate objectives, including growth in the U.S. commercial team to launch Zircaix®<sup>3</sup>, Pixclara™<sup>3</sup> and TLX007-CDx, in addition to executing on current active clinical studies globally, including the ProstACT GLOBAL Phase III trial.

Managing Director and Group CEO Dr. Christian Behrenbruch stated, "While this is not our desired outcome Telix's strategic objectives must align with our duty to existing shareholders. I'd like to thank my team for the personal commitment and incredibly long hours put into this IPO process."

Telix's ordinary shares have been in trading halt since 13 June 2024 and are expected to resume trading on ASX today.

#### **Investor conference call**

An investor conference call will be hosted today, Friday 14<sup>th</sup> June 2024 at 9.30am AEST (Thursday 13<sup>th</sup> June 7.30pm ET).

Please register at the following link and dial-in details will be provided: <https://s1.c-conf.com/diamondpass/10039822-om3ebv.html>

#### **About Telix Pharmaceuticals Limited**

Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial

<sup>1</sup> ASX disclosure 5 June 2024.

<sup>2</sup> ASX disclosure 4 January 2024.

<sup>3</sup> Brand names subject to regulatory approval.

---

stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Telix's lead imaging product, gallium-68 (<sup>68</sup>Ga) gozetotide injection (also known as <sup>68</sup>Ga PSMA-11 and marketed under the brand name Illucix®), has been approved by the U.S. Food and Drug Administration (FDA)<sup>4</sup>, by the Australian Therapeutic Goods Administration (TGA)<sup>5</sup>, and by Health Canada<sup>6</sup>. No other Telix product has received a marketing authorisation in any jurisdiction.

Visit [www.telixpharma.com](http://www.telixpharma.com) for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on [X](#) and [LinkedIn](#).

## Telix Investor Relations

Ms. Kyahn Williamson  
Telix Pharmaceuticals Limited  
SVP Investor Relations and Corporate Communications  
Email: [kyahn.williamson@telixpharma.com](mailto:kyahn.williamson@telixpharma.com)

*This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.*

## Legal Notices

*The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. The information contained in this announcement is subject to change without notification.*

*This announcement may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.*

*To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.*

*©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals® and Illucix® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.*

---

<sup>4</sup> Telix ASX disclosure 20 December 2021.

<sup>5</sup> Telix ASX disclosure 2 November 2021.

<sup>6</sup> Telix ASX disclosure 14 October 2022.